Beruflich Dokumente
Kultur Dokumente
02
04
05
06
07
08
09
10
11
CST
VCT
Test
HIV(+)
HIV (+)
Komul
atif
ART
PMTCT
Wafat
1
1
1
1
1
2
1
2
4
17
5
9
2
1
15
14
32
19
ARV
NRTI
NNRTI
PI
Nucleoside
Non Nucleoside
Protease Inhibitor
Reverse Transcriptase Reverse
Inhibitor
Transcriptase Inhibitor
ES:
Toksisitas Mitokondria
ES:
Hipersensitivitas
ES:
Gangguan Metabolik
ARV
NRTI
NNRTI
PI
AZT (Zidovudin)
3TC (Lamivudin)
FTC (Amcitabrin)
d4T (Stavudin)
TDF (Tenofovir)
NVP (Nevirapine)
LPV/r
(Lopinavir/Ritonavir)
EFZ (Efavirenz)
ARV
NVP
AZT
3TC
d4T
EFV
Anemia
Netropeni
a
Asidosis
laktat
ARV
Rash
Diare
Netropeni
a
NVP
AZT
3TC
Lipoatrof
Gangg
metabolik
Asidosis
laktat
d4T
EFV
Teratogenic
Depresi
Ansietas
Diare
Rash
ARV
NVP
AZT
3TC
d4T
EFV
ARV
NVP
AZT
3TC
d4T
EFV
ARV
NVP
AZT
3TC
d4T
EFV
ARV
AZT
NVP
3TC
d4T
EFV
ARV
AZT
NVP
3TC
FTC
d4T
TDF
EFV
When to start
All adolescents and adults
including pregnant women with
HIV infection and CD4 counts of
350 cells/mm3, should start
ART, regardless of the presence
or absence of clinical
symptoms.
Those with severe or advanced
clinical disease (WHO clinical
stage 3 or 4) should start ART
irrespective of their CD4 cell
count.
Co-trimoxazole
Co-trimoxazole prophylaxis is a simple,
well-tolerated and cost-effective
intervention for people living with HIV.
It should be implemented as an
integral component of the HIV chronic
care package and as a key element of
preantiretroviral therapy care.
Co-trimoxazole prophylaxis needs to
continue after antiretroviral therapy is
initiated until there is evidence of
immune recovery (see subsections 6.4
and 7.6).
Co-trimoxazole
Discontinuation of CTX
Discontinuation of CTX